APA

Phyo A. P., Jittamala P., Nosten F. H., Pukrittayakamee S., Imwong M., White N. J., Duparc S., Macintyre F., Baker M. & Möhrle J. J. (20160613). Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial. : The Lancet. Infectious diseases.

Chicago

Phyo Aung Pyae, Jittamala Podjanee, Nosten François H, Pukrittayakamee Sasithon, Imwong Mallika, White Nicholas J, Duparc Stephan, Macintyre Fiona, Baker Mark and Möhrle Jörg J. 20160613. Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial. : The Lancet. Infectious diseases.

Harvard

Phyo A. P., Jittamala P., Nosten F. H., Pukrittayakamee S., Imwong M., White N. J., Duparc S., Macintyre F., Baker M. and Möhrle J. J. (20160613). Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial. : The Lancet. Infectious diseases.

MLA

Phyo Aung Pyae, Jittamala Podjanee, Nosten François H, Pukrittayakamee Sasithon, Imwong Mallika, White Nicholas J, Duparc Stephan, Macintyre Fiona, Baker Mark and Möhrle Jörg J. Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial. : The Lancet. Infectious diseases. 20160613.